Selective decontamination of the digestive tract and selective oropharyngeal decontamination in intensive care unit patients: A cost-effectiveness analysis

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Oostdijk, Evelien A N ^a   De Wit, G A ^a,b   Bakker, Marina ^a   De Smet, Anne Marie G A ^c   Bonten, M J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CARBAPENEM; CEFOTAXIME; CLINDAMYCIN; COLISTIN; PENICILLIN DERIVATIVE; TOBRAMYCIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; COST EFFECTIVENESS ANALYSIS; DRUG USE; ECONOMIC EVALUATION; FEMALE; GASTROINTESTINAL INFECTION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; INFECTION PREVENTION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OROPHARYNGEAL INFECTION; PATIENT CARE; PHARYNGITIS; POST HOC ANALYSIS; SELECTIVE DIGESTIVE TRACT DECONTAMINATION; SELECTIVE OROPHARYNGEAL DECONTAMINATION; SENSITIVITY ANALYSIS;

EID: 84876113055     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002529     Document Type: Article

References (42)

1. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003;361:2068-77.
2. Bearman GM, Munro C, Sessler CN, et al. Infection control and the prevention of nosocomial infections in the intensive care unit. Semin Respir Crit Care Med 2006;27:310-24. (Pubitemid 44061632)
3. de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009;360:20-31.
4. Wunderink RG. Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med 2010;181:426-7.
5. Liberati A, D'Amico R, Pifferi S, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009;(4):CD000022.
6. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
7. Dodek P, Keenan S, Cook D, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004;141:305-13. (Pubitemid 39079293)
8. Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention (U.S.). Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care 2004;49:926-39.
9. Torres A, Carlet J. Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia. Eur Respir J 2001;17:1034-45.
10. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2005.
11. Hakkaart-Van Roijen L, Tan SS, Bouwmans CA. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg., 2011.
12. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: Design, conduct, analysis, and reporting. BMJ 2011;342:d1548.
13. Boersma C, Carides GW, Atthobari J, et al. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Clin Ther 2007;29:963-71. (Pubitemid 47223431)
14. Simoens S. Health economic assessment: A methodological primer. Int J Environ Res Public Health 2009;6:2950-66.
15. Al Maiwenn MJ, Hakkaart L, Tan SS, et al. Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Crit Care 2010;14:R195.
16. Dasta JF, McLaughlin TP, Mody SH, et al. Daily cost of an intensive care unit day: The contribution of mechanical ventilation. Crit Care Med 2005;33:1266-71. (Pubitemid 40827376)
17. Tan SS, Hakkaart-van Roijen L, Al MJ, et al. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med 2008;23:250-7.
18. The Dutch Drug Information System of the Health Care Insurance Board. http://www.gipdatabank.nl (accessed 20 March 2012).
19. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10:587-99. (Pubitemid 32998371)
20. De Wit GA, Tariq L, Van Gils PF, et al. Handleiding voor economisch evaluatieonderzoek bij gezondheidsbevordering: Over Euro en Effect, 2010.
21. Centraal Bureau Voor de Statistiek. Levensverwachting; geslacht en leeftijd, 2012.
22. Obenchain RL. Resampling and multiplicity in cost-effectiveness inference. J Biopharm Stat 1999;9:563-82. (Pubitemid 29535948)
23. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Stat Methods Med Res 2002;11:455-68. (Pubitemid 36096865)
24. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15. (Pubitemid 38660390)
25. van der Voort PH, van Roon EN, Kampinga GA, et al. A before-after study of multi-resistance and cost of selective decontamination of the digestive tract. Infection 2004;32:271-7. (Pubitemid 39319143)
26. Abele-Horn M, Dauber A, Bauernfeind A, et al. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Intensive Care Med 1997;23:187-95. (Pubitemid 27110395)
27. Langlois-Karaga A, Bues-Charbit M, Davignon A, et al. Selective digestive decontamination in multiple trauma patients: Cost and efficacy. Pharm World Sci 1995;17:12-16.
28. Sanchez Garcia M, Cambronero Galache JA, Lopez Diaz J, et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 1998;158:908-16. (Pubitemid 28449460)
29. Bergmans DC, Bonten MJ, Gaillard CA, et al. Prevention of ventilator-associated pneumonia by oral decontamination: A prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001;164:382-8. (Pubitemid 32778203)
30. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: The NASCENT randomized trial. JAMA 2008;300:805-13.
31. Shorr AF, Zilberberg MD, Kollef M. Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2009;30:759-63.
32. Muscedere J, Rewa O, McKechnie K, et al. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis. Crit Care Med 2011;39:1985-91.
33. Hallais C, Merle V, Guitard PG, et al. Is continuous subglottic suctioning cost-effective for the prevention of ventilator-associated pneumonia? Infect Control Hosp Epidemiol 2011;32:131-5.
34. Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia: Potential economic implications. Chest 2001;119:228-35. (Pubitemid 32150572)
35. Normand S, Francois B, Darde ML, et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Med 2005;31:1508-13. (Pubitemid 41598661)
36. Oostdijk EA, de Smet AM, Blok HE, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010;181:452-7.
37. de Smet AM, Kluytmans JA, Blok HE, et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: An open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011;11:372-80.
38. Oostdijk EA, de Smet AM, Kesecioglu J, et al. Decontamination of cephalosporin-resistant Enterobacteriaceae during selective digestive tract decontamination in intensive care units. J Antimicrob Chemother 2012;67:2250-3.
39. Oostdijk EA, Smits L, de Smet AM, et al. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 2012; 1 Dec 2012 [Epub ahead of print].
40. Walden AP, Bonten MJ, Wise MP. Should selective digestive decontamination be used in critically ill patients? BMJ 2012;345: E6697.
41. Ioannidis JP, Garber AM. Individualized cost-effectiveness analysis. PLoS Med 2011;8:e1001058.
42. Internal Revenue Service.